Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Vaccines

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 103 articles:
HTML format
Text format



Single Articles


    February 2017
  1. SUTTER RW, Okayasu H, Kieny MP
    Next generation inactivated poliovirus vaccine: The future has arrived.
    Clin Infect Dis. 2017 Feb 14. doi: 10.1093.
    PubMed     Text format    


  2. LEVI M, Ravaldi C, Pontello V, Bonaiuti R, et al
    Influenza vaccination and stillbirth prevention in high income countries: Is it really that effective?
    Clin Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


  3. OLARTE L, Barson WJ, Barson RM, Romero JR, et al
    Pneumococcal Pneumonia Requiring Hospitalization in U.S. Children in the 13-Valent Pneumococcal Conjugate Vaccine Era.
    Clin Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


  4. FERDINANDS JM, Fry AM, Reynolds S, Petrie JG, et al
    Intraseason Waning of Influenza Vaccine Protection: Evidence From the US Influenza Vaccine Effectiveness Network, 2011-2012 Through 2014-2015.
    Clin Infect Dis. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    


  5. SOETERS HM, Whaley M, Alexander-Scott N, Kanadanian KV, et al
    Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college - Rhode Island, 2015-2016.
    Clin Infect Dis. 2017 Feb 4. doi: 10.1093.
    PubMed     Text format    


    December 2016
  6. FERDINANDS JM, Fry AM, Reynolds S, Petrie J, et al
    Intraseason waning of influenza vaccine protection: Evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through 2014-15.
    Clin Infect Dis. 2016 Dec 29. pii: ciw816. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. TOH ZQ, Russell FM, Reyburn R, Fong J, et al
    Sustained antibody responses six years following one, two, or three doses of quadrivalent HPV vaccine in adolescent Fijian girls, and subsequent responses to a single dose of bivalent HPV vaccine: a prospective cohort study.
    Clin Infect Dis. 2016 Dec 28. pii: ciw865. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. LIN A, Ong KJ, Hobbelen P, King E, et al
    Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men.
    Clin Infect Dis. 2016 Dec 23. pii: ciw845. doi: 10.1093.
    PubMed     Text format     Abstract available


  9. LARSON HJ
    Japanese media and the HPV vaccine saga.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  10. PATEL LN, Arciuolo R, Fu J, Giancotti FR, et al
    Mumps Outbreak among a Highly Vaccinated University Community - New York City, NY, January - April 2014.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  11. MAERTENS K, Hoang TT, Nguyen TD, Cabore RN, et al
    The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam.
    Clin Infect Dis. 2016;63.
    PubMed     Text format     Abstract available


    November 2016
  12. KONDO Y, Tanimoto T, Kosugi K, Tsuda K, et al
    Measles Vaccination for International Airport Workers.
    Clin Infect Dis. 2016 Nov 15. pii: ciw769. doi: 10.1093.
    PubMed     Text format    


    October 2016
  13. JAYASINGHE S, Menzies R, Chiu C, Toms C, et al
    Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  14. NEVEN B, Perot P, Bruneau J, Pasquet M, et al
    Cutaneous and Visceral Chronic Granulomatous Disease Triggered by a Rubella Virus Vaccine Strain in Children With Primary Immunodeficiencies.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  15. ZIMMERMAN RK, Nowalk MP, Chung J, Jackson ML, et al
    2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  16. OMER SB, Yildirim I
    Influenza Vaccine Effectiveness: A Glass both Half Full and Half Empty.
    Clin Infect Dis. 2016.
    PubMed     Text format    


    September 2016
  17. TSUDA K, Yamamoto K, Leppold C, Tanimoto T, et al
    Trends of media coverage on human papillomavirus vaccination in Japanese newspapers.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  18. KAHN JA, Widdice LE, Ding L, Huang B, et al
    Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  19. WINTER K, Cherry JD, Harriman K
    Effectiveness of prenatal Tdap vaccination on pertussis severity in infants.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  20. WINTER K, Nickell S, Powell M, Harriman K, et al
    Effectiveness of prenatal versus postpartum Tdap vaccination in preventing infant pertussis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  21. BAXTER R, Lewis E, Goddard K, Fireman B, et al
    Acute demyelinating events following vaccines - a case centered analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  22. SKOWRONSKI DM, Chambers C, Gilca R, De Serres G, et al
    Repeat Influenza Vaccination and High-dose Efficacy.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  23. HAVERS FP, Sokolow L, Shay DK, Farley MM, et al
    Case-control study of vaccine effectiveness in preventing laboratory-confirmed influenza hospitalizations in older adults, United States, 2010-11.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    July 2016
  24. NOHO-KONTEH F, Adetifa JU, Cox M, Hossin S, et al
    Sex-differential non-vaccine specific immunological effects of diphtheria-tetanus-pertussis and measles vaccination.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  25. PETRIE JG, Ohmit SE, Cheng CK, Martin ET, et al
    Influenza Vaccine Effectiveness against Antigenically Drifted Influenza Higher than Expected in Hospitalized Adults: 2014-2015.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    June 2016
  26. DOLL MK, Morrison KT, Buckeridge DL, Quach C, et al
    Two Birds with One Stone: Estimating Population Vaccination Coverage from a Test-Negative Vaccine Effectiveness Case-Control Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    May 2016
  27. GARLAND SM, Kjaer SK, Munoz N, Block SL, et al
    Impact and Effectiveness Of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of Ten Years of Real-World Experience.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  28. BEN-SHIMOL S, Givon-Lavi N, Leibovitz E, Raiz S, et al
    The impact of the widespread introduction of pneumococcal conjugate vaccines on pneumococcal and non-pneumococcal otitis media.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  29. COLGATE ER, Haque R, Dickson DM, Carmolli MP, et al
    A Randomized Controlled Trial with Delayed Dosing of Oral Rotavirus Vaccine Demonstrates Decreased Risk of Rotavirus Gastroenteritis Associated with Serum Zinc.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  30. KNISELY JM, Liu B, Ranallo RT, Zou L, et al
    Vaccines for Hospital-Associated Infections: Promise and Challenge.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  31. HATHERILL M, Scriba TJ, Udwadia ZF, Mullerpattan JB, et al
    BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers.
    Clin Infect Dis. 2016;62 Suppl 3:S262-7.
    PubMed     Text format     Abstract available



  32. Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-sectional Analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  33. OLSEN SJ, Mirza SA, Vonglokham P, Khanthamaly V, et al
    The Effect of Influenza Vaccination on Birth Outcomes in a Cohort of Pregnant Women in Lao PDR, 2014-2015.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  34. HAMMARLUND E, Thomas A, Poore EA, Amanna IJ, et al
    Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-sectional Analysis.
    Clin Infect Dis. 2016;62:1111-8.
    PubMed     Text format     Abstract available


  35. PARASHAR UD, Johnson H, Steele AD, Tate JE, et al
    Health Impact of Rotavirus Vaccination in Developing Countries: Progress and Way Forward.
    Clin Infect Dis. 2016;62 Suppl 2:S91-5.
    PubMed     Text format     Abstract available


  36. BAR-ZEEV N, Tate JE, Pecenka C, Chikafa J, et al
    Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient-Level Costing Data.
    Clin Infect Dis. 2016;62 Suppl 2:S220-8.
    PubMed     Text format     Abstract available


  37. BAR-ZEEV N, Jere KC, Bennett A, Pollock L, et al
    Population Impact and Effectiveness of Monovalent Rotavirus Vaccination in Urban Malawian Children 3 Years After Vaccine Introduction: Ecological and Case-Control Analyses.
    Clin Infect Dis. 2016;62 Suppl 2:S213-9.
    PubMed     Text format     Abstract available


  38. TATE JE, Ngabo F, Donnen P, Gatera M, et al
    Effectiveness of Pentavalent Rotavirus Vaccine Under Conditions of Routine Use in Rwanda.
    Clin Infect Dis. 2016;62 Suppl 2:S208-12.
    PubMed     Text format     Abstract available


  39. ARMAH G, Pringle K, Enweronu-Laryea CC, Ansong D, et al
    Impact and Effectiveness of Monovalent Rotavirus Vaccine Against Severe Rotavirus Diarrhea in Ghana.
    Clin Infect Dis. 2016;62 Suppl 2:S200-7.
    PubMed     Text format     Abstract available


  40. TSOLENYANU E, Mwenda JM, Dagnra A, Leshem E, et al
    Early Evidence of Impact of Monovalent Rotavirus Vaccine in Togo.
    Clin Infect Dis. 2016;62 Suppl 2:S196-9.
    PubMed     Text format     Abstract available


  41. GROOME MJ, Zell ER, Solomon F, Nzenze S, et al
    Temporal Association of Rotavirus Vaccine Introduction and Reduction in All-Cause Childhood Diarrheal Hospitalizations in South Africa.
    Clin Infect Dis. 2016;62 Suppl 2:S188-95.
    PubMed     Text format     Abstract available


  42. MPABALWANI EM, Simwaka CJ, Mwenda JM, Mubanga CP, et al
    Impact of Rotavirus Vaccination on Diarrheal Hospitalizations in Children Aged <5 Years in Lusaka, Zambia.
    Clin Infect Dis. 2016;62 Suppl 2:S183-7.
    PubMed     Text format     Abstract available


  43. BERES LK, Tate JE, Njobvu L, Chibwe B, et al
    A Preliminary Assessment of Rotavirus Vaccine Effectiveness in Zambia.
    Clin Infect Dis. 2016;62 Suppl 2:S175-82.
    PubMed     Text format     Abstract available


  44. ENANE LA, Gastanaduy PA, Goldfarb DM, Pernica JM, et al
    Impact of Rotavirus Vaccination on Hospitalizations and Deaths From Childhood Gastroenteritis in Botswana.
    Clin Infect Dis. 2016;62 Suppl 2:S168-74.
    PubMed     Text format     Abstract available


  45. GASTANADUY PA, Steenhoff AP, Mokomane M, Esona MD, et al
    Effectiveness of Monovalent Rotavirus Vaccine After Programmatic Implementation in Botswana: A Multisite Prospective Case-Control Study.
    Clin Infect Dis. 2016;62 Suppl 2:S161-7.
    PubMed     Text format     Abstract available


  46. LESHEM E, Givon-Lavi N, Tate JE, Greenberg D, et al
    Real-World Effectiveness of Pentavalent Rotavirus Vaccine Among Bedouin and Jewish Children in Southern Israel.
    Clin Infect Dis. 2016;62 Suppl 2:S155-60.
    PubMed     Text format     Abstract available


  47. SAHAKYAN G, Grigoryan S, Wasley A, Mosina L, et al
    Impact and Effectiveness of Monovalent Rotavirus Vaccine in Armenian Children.
    Clin Infect Dis. 2016;62 Suppl 2:S147-54.
    PubMed     Text format     Abstract available


  48. GHEORGHITA S, Birca L, Donos A, Wasley A, et al
    Impact of Rotavirus Vaccine Introduction and Vaccine Effectiveness in the Republic of Moldova.
    Clin Infect Dis. 2016;62 Suppl 2:S140-6.
    PubMed     Text format     Abstract available


  49. SANCHEZ-URIBE E, Esparza-Aguilar M, Parashar UD, Richardson V, et al
    Sustained Reduction of Childhood Diarrhea-Related Mortality and Hospitalizations in Mexico After Rotavirus Vaccine Universalization.
    Clin Infect Dis. 2016;62 Suppl 2:S133-9.
    PubMed     Text format     Abstract available


  50. PATEL M, Pedreira C, De Oliveira LH, Tate J, et al
    Effectiveness of Pentavalent Rotavirus Vaccine Against a Diverse Range of Circulating Strains in Nicaragua.
    Clin Infect Dis. 2016;62 Suppl 2:S127-32.
    PubMed     Text format     Abstract available


  51. GASTANADUY PA, Contreras-Roldan I, Bernart C, Lopez B, et al
    Effectiveness of Monovalent and Pentavalent Rotavirus Vaccines in Guatemala.
    Clin Infect Dis. 2016;62 Suppl 2:S121-6.
    PubMed     Text format     Abstract available


  52. PRINGLE KD, Patzi M, Tate JE, Iniguez Rojas V, et al
    Sustained Effectiveness of Rotavirus Vaccine Against Very Severe Rotavirus Disease Through the Second Year of Life, Bolivia 2013-2014.
    Clin Infect Dis. 2016;62 Suppl 2:S115-20.
    PubMed     Text format     Abstract available


  53. TATE JE, Patel MM, Cortese MM, Payne DC, et al
    Use of Patients With Diarrhea Who Test Negative for Rotavirus as Controls to Estimate Rotavirus Vaccine Effectiveness Through Case-Control Studies.
    Clin Infect Dis. 2016;62 Suppl 2:S106-14.
    PubMed     Text format     Abstract available


  54. TATE JE, Burton AH, Boschi-Pinto C, Parashar UD, et al
    Global, Regional, and National Estimates of Rotavirus Mortality in Children <5 Years of Age, 2000-2013.
    Clin Infect Dis. 2016;62 Suppl 2:S96-S105.
    PubMed     Text format     Abstract available


    April 2016

  55. Antibody Responses After Primary Immunization in Infants Born to Women Receiving a Pertussis-containing Vaccine During Pregnancy: Single Arm Observational Study With a Historical Comparator.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  56. GREENBERG D, Lee JT
    Pneumococcal Vaccination in Adults: Do We Have to Recalculate Our Approach?
    Clin Infect Dis. 2016.
    PubMed     Text format    


  57. CABAJ JL, Nettel-Aguirre A, MacDonald J, Vanderkooi OG, et al
    Influence of Childhood Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Adults With Underlying Comorbidities in Calgary, Alberta (2000-2013).
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  58. BAXTER R, Lewis E, Fireman B, DeStefano F, et al
    Case centered analysis of Optic Neuritis following vaccines.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  59. EBERHARDT CS, Blanchard-Rohner G, Lemaitre B, Boukrid M, et al
    Maternal Immunization Earlier in Pregnancy Maximizes Antibody Transfer and Expected Infant Seropositivity Against Pertussis.
    Clin Infect Dis. 2016;62:829-36.
    PubMed     Text format     Abstract available


  60. THEILACKER C, Ludewig K, Serr A, Schimpf J, et al
    Overwhelming Postsplenectomy Infection: A Prospective Multicenter Cohort Study.
    Clin Infect Dis. 2016;62:871-8.
    PubMed     Text format     Abstract available


    March 2016
  61. REGAN AK, Moore HC, de Klerk N, Omer SB, et al
    Seasonal Trivalent Influenza Vaccination During Pregnancy and the Incidence of Stillbirth: Population-Based Retrospective Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  62. SKOWRONSKI DM, Chambers C, Sabaiduc S, De Serres G, et al
    A perfect storm: Impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014-15 season.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  63. TOSTI ME, Alfonsi V, Lacorte E, Mele A, et al
    Acute hepatitis B after the implementation of universal vaccination in Italy: results from a 22-years surveillance (1993-2014).
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  64. CHEN WH, Cohen MB, Kirkpatrick BD, Brady RC, et al
    Single-Dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection with Vibrio cholerae O1 El Tor.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  65. HARRIS JB
    Resurrecting a live oral cholera vaccine.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  66. STEELE AD, Hay Burgess DC, Diaz Z, Carey ME, et al
    Challenges and Opportunities for Typhoid Fever Control: A Call for Coordinated Action.
    Clin Infect Dis. 2016;62 Suppl 1:S4-8.
    PubMed     Text format     Abstract available


    February 2016
  67. DIAZGRANADOS CA, Dunning AJ, Robertson CA, Talbot HK, et al
    Effect of previous year vaccination on the efficacy, immunogenicity, and safety of high-dose inactivated influenza vaccine in older adults.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  68. GOODMAN JL
    Investing in Immunity: Prepandemic Immunization to Combat Future Influenza Pandemics.
    Clin Infect Dis. 2016;62:495-8.
    PubMed     Text format     Abstract available


  69. FULTON TR, Phadke VK, Orenstein WA, Hinman AR, et al
    Protective Effect of Contemporary Pertussis Vaccines: A Systematic Review and Meta-analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  70. TOMCZYK SM, Lynfield R, Schaffner W, Reingold A, et al
    Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    January 2016
  71. RAPOSE A
    Improved Measles Vaccination: Contributions of a Travel Clinic.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  72. MUSHER DM
    Genetic Control of Antibody Responses to Pneumococcal Capsular Polysaccharides.
    Clin Infect Dis. 2016;62:132-3.
    PubMed     Text format    


  73. BROUSSEAU N, Slack MP, Waight P, Borrow R, et al
    Reply to Musher.
    Clin Infect Dis. 2016;62:133-4.
    PubMed     Text format    


    December 2015
  74. SENA AC, Hsu KK, Kellogg N, Girardet R, et al
    Sexual Assault and Sexually Transmitted Infections in Adults, Adolescents, and Children.
    Clin Infect Dis. 2015;61 Suppl 8:S856-64.
    PubMed     Text format     Abstract available


  75. PARK IU, Introcaso C, Dunne EF
    Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.
    Clin Infect Dis. 2015;61 Suppl 8:S849-55.
    PubMed     Text format     Abstract available


  76. TSENG HF, Luo Y, Shi J, Sy LS, et al
    Effectiveness of Herpes Zoster Vaccine in Patients 60 Years and Older With End-stage Renal Disease.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    November 2015
  77. TREANOR J
    Is pre-pandemic vaccination a wise investment?
    Clin Infect Dis. 2015.
    PubMed     Text format    


  78. KARACHALIOU A, Conlan AJ, Preziosi MP, Trotter CL, et al
    Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt.
    Clin Infect Dis. 2015;61 Suppl 5:S594-600.
    PubMed     Text format     Abstract available


  79. ROY CHOWDHURY P, Meier C, Laraway H, Tang Y, et al
    Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali.
    Clin Infect Dis. 2015;61 Suppl 5:S586-93.
    PubMed     Text format     Abstract available


  80. BORROW R, Tang Y, Yakubu A, Kulkarni PS, et al
    MenAfriVac as an Antitetanus Vaccine.
    Clin Infect Dis. 2015;61 Suppl 5:S570-7.
    PubMed     Text format     Abstract available


  81. HOLME D, Findlow H, Sow SO, Idoko OT, et al
    Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination.
    Clin Infect Dis. 2015;61 Suppl 5:S563-9.
    PubMed     Text format     Abstract available


  82. PRICE GA, Hollander AM, Plikaytis BD, Mocca BT, et al
    Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays.
    Clin Infect Dis. 2015;61 Suppl 5:S554-62.
    PubMed     Text format     Abstract available


  83. BASTA NE, Borrow R, Berthe A, Dembele AT, et al
    Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
    Clin Infect Dis. 2015;61 Suppl 5:S547-53.
    PubMed     Text format     Abstract available


  84. DIALLO A, Sow SO, Idoko OT, Hirve S, et al
    Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
    Clin Infect Dis. 2015;61 Suppl 5:S521-30.
    PubMed     Text format     Abstract available


  85. TAPIA MD, Findlow H, Idoko OT, Preziosi MP, et al
    Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.
    Clin Infect Dis. 2015;61 Suppl 5:S514-20.
    PubMed     Text format     Abstract available


  86. ENWERE GC, Paranjape G, Kulkarni PS, Ginde M, et al
    Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description, Challenges, and Lessons.
    Clin Infect Dis. 2015;61 Suppl 5:S501-6.
    PubMed     Text format     Abstract available


  87. VANNICE KS, Keita M, Sow SO, Durbin AP, et al
    Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali.
    Clin Infect Dis. 2015;61 Suppl 5:S493-500.
    PubMed     Text format     Abstract available


  88. KULKARNI PS, Socquet M, Jadhav SS, Kapre SV, et al
    Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India.
    Clin Infect Dis. 2015;61 Suppl 5:S483-8.
    PubMed     Text format     Abstract available


  89. COLOMBINI A, Trotter C, Madrid Y, Karachaliou A, et al
    Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso.
    Clin Infect Dis. 2015;61 Suppl 5:S473-82.
    PubMed     Text format     Abstract available


  90. DIOMANDE FV, Yameogo TM, Vannice KS, Preziosi MP, et al
    Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013.
    Clin Infect Dis. 2015;61 Suppl 5:S459-66.
    PubMed     Text format     Abstract available


  91. BERLIER M, Barry R, Shadid J, Sirica C, et al
    Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa.
    Clin Infect Dis. 2015;61 Suppl 5:S451-8.
    PubMed     Text format     Abstract available


  92. CIBRELUS L, Lingani C, Fernandez K, Djingarey MH, et al
    Risk Assessment and Meningococcal A Conjugate Vaccine Introduction in Africa: The District Prioritization Tool.
    Clin Infect Dis. 2015;61 Suppl 5:S442-50.
    PubMed     Text format     Abstract available


  93. DJINGAREY MH, Diomande FV, Barry R, Kandolo D, et al
    Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.
    Clin Infect Dis. 2015;61 Suppl 5:S434-41.
    PubMed     Text format     Abstract available


  94. DELLEPIANE N, Akanmori BD, Gairola S, Jadhav SS, et al
    Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries.
    Clin Infect Dis. 2015;61 Suppl 5:S428-33.
    PubMed     Text format     Abstract available


  95. MARTELLET L, Sow SO, Diallo A, Hodgson A, et al
    Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine.
    Clin Infect Dis. 2015;61 Suppl 5:S422-7.
    PubMed     Text format     Abstract available


  96. IDOKO OT, Diallo A, Sow SO, Hodgson A, et al
    Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials.
    Clin Infect Dis. 2015;61 Suppl 5:S416-21.
    PubMed     Text format     Abstract available


  97. FRASCH CE, Kapre SV, Lee CH, Preaud JM, et al
    Technical Development of a New Meningococcal Conjugate Vaccine.
    Clin Infect Dis. 2015;61 Suppl 5:S404-9.
    PubMed     Text format     Abstract available


  98. TIFFAY K, Jodar L, Kieny MP, Socquet M, et al
    The Evolution of the Meningitis Vaccine Project.
    Clin Infect Dis. 2015;61 Suppl 5:S396-403.
    PubMed     Text format     Abstract available


  99. AGUADO MT, Jodar L, Granoff D, Rabinovich R, et al
    From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project.
    Clin Infect Dis. 2015;61 Suppl 5:S391-5.
    PubMed     Text format     Abstract available


  100. OKWO-BELE JM, LaForce FM, Borrow R, Preziosi MP, et al
    Documenting the Results of a Successful Partnership: A New Meningococcal Vaccine for Africa.
    Clin Infect Dis. 2015;61 Suppl 5:S389-90.
    PubMed     Text format    


  101. SAMBO L, Chan M, Davis S, Lake A, et al
    A Vaccine Meets Its Promise: Success in Controlling Epidemic Meningitis in Sub-Saharan Africa.
    Clin Infect Dis. 2015;61 Suppl 5:S387-8.
    PubMed     Text format    


  102. PETRIE JG, Cheng C, Malosh RE, VanWormer JJ, et al
    Illness Severity and Work Productivity Loss among Working Adults with Medically-Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012-2013.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    September 2015
  103. PURSWANI MU, Karalius B, Yao TJ, Schmid DS, et al
    Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: